Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fenfluramine in Lennox-Gastaut Syndrome
NCT03355209Phase 3Completed
- Sponsor
- Zogenix, Inc.
- Start
- Nov 2017
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 14
01
Overview
A Phase 3 trial of fenfluramine in Lennox-Gastaut syndrome (LGS), sponsored by Zogenix, Inc.. Started Nov 2017; status: completed.
02
Drugs
fenfluramine
03
Conditions
Lennox-Gastaut syndrome (LGS)
Beyond the preview
Go deeper on NCT03355209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03355209.